Shaanxi BLOOM Tech Co., Ltd. yog ib qho ntawm cov tuam ntxhab thiab cov muag khoom ntawm survodutide txhaj tshuaj hauv Suav teb. Txais tos rau cov lag luam wholesale bulk zoo survodutide txhaj rau muag ntawm no los ntawm peb lub hoobkas. Kev pabcuam zoo thiab tus nqi tsim nyog muaj.
Survodutide txhaj tshuajnthuav qhia qhov tsis sib xws hauv peptide formulation science-nws qhov kev ruaj ntseg hauv cov qauv prefilled cwjmem belies ib tug zais susceptibility rau interfacial denaturation ntawm huab cua-kua ciam teb, ib tug tshwm sim feem ntau txuam nrog monoclonal antibodies es tsis peptides. Kev txhaj tshuaj subvisible particle suav nce los ntawm 300% tom qab simulated shipping vibrations, taug qab rau shear-induced nucleation ntawm peptide fibrils ntawm silicone roj-microbubble interfaces nyob rau hauv lub cartridge, ib tug artifact ntawm lub stopper lubrication txheej txheem. Qhov "kev sib sau ntsiag to" no tshem tawm cov qauv QC kev sim tab sis tuaj yeem piav qhia txog 8% cov neeg mob sab nraud hauv Phase 3 kev sim uas qhia cov lus teb qis glycemic. Cov txheej txheem siv m-cresol li preservative- txawv txawv rau dual agonists- tsim cryptic coordination complexes nrog Survodutide's histidine residues, kuaj tau tsuas yog los ntawm synchrotron X-ray absorption spectroscopy, uas tab tom ua kom tsis muaj zog. destabilizing ntu GLP-1.
|
|
|
Survodutide hmoov COA
Kev Tshawb Fawb Txog Kev Tsim Kho Kev Xa Khoom Tshiab
Survodutide (BI 456906) yog ib qho tshiab dual agonist ntawm glucagon receptor (GCGR) thiab glucagon-zoo li peptide-1 receptor (GLP-1R), ua tiav ntev- lub sij hawm poob thiab kev tswj hwm metabolic los ntawm kev txhaj tshuaj subcutaneous ib zaug. Kev tshawb nrhiav ntawm nws cov thev naus laus zis tshiab tsom mus rau kev txhim kho cov tshuaj ruaj khov, txhim kho cov yam ntxwv ntawm cov tshuaj pharmacokinetic, txhim kho cov neeg mob ua raws, thiab txhim kho cov tswv yim xa tawm nrog rau kev kho mob xav tau (xws li rog rog, metabolic dysfunction ntsig txog fatty siab kab mob, MASH).
Molecular yam ntxwv thiab kev xa khoom sib tw ntawm Survodutide txhaj
Survodutide yog ib qho -molecule acylated peptide uas tswj cov metabolism hauv lub zog los ntawm kev ua haujlwm ib txhij ntawm GCGR thiab GLP-1R: nws inhibits qab los noj mov, nce kev siv hluav taws xob, thiab txhim kho insulin rhiab heev. Nws cov qauv molecular muaj xws li:
Acylation hloov kho:Los ntawm kev khi rau albumin los ntawm cov roj ntsha fatty acid, ib nrab - lub neej tau txuas mus rau ib zaug - kev tswj hwm txhua lub lim tiam;
Dual{0}}lub hom phiaj kev ua:Nws yog ib qho tsim nyog yuav tsum tswj hwm qhov sib npaug ntawm GCGR / GLP-1R ua kom tsis txhob muaj kev phiv tshwm sim los ntawm kev ua kom ntau dhau ntawm ib lub hom phiaj (xws li kev ua kom GCGR ntau dhau tuaj yeem ua rau hyperglycemia).
Kev sib tw xa khoom:
Kev ruaj ntseg: cov tshuaj Peptide yog qhov cuam tshuam rau kev degradation enzymatic thiab tshuaj degradation, thiab cov formulation yuav tsum tau optimized kom muaj kev ua si;
Bioavailability: Tom qab txhaj tshuaj subcutaneous, cov tshuaj yuav tsum tau nqus sai sai thiab tso tawm kom ruaj khov kom tsis txhob muaj kev hloov pauv hauv cov ntshav tshuaj concentration;
Targeting: Thaum tsom cov kab mob siab (xws li MASH), cov tshuaj yuav tsum tau nce nws cov kev faib tawm hauv daim siab.
Tshawb nrhiav cov lus qhia txog kev xa khoom tshiab
Nanocarrier xa khoom system
Lub hauv paus ntsiab lus: Encapsulate Survodutide nyob rau hauv nanoparticles (xws li liposomes, polymer nanoparticles, thiab inorganic nanoparticles) los txhim kho nws solubility, stability, thiab lub hom phiaj muaj peev xwm.
Muaj peev xwm siv tau:
Lub sij hawm nthuav dav ntxiv: Kev hloov kho saum npoo nrog polyethylene glycol (PEG) txo qis kev tiv thaiv kab mob thiab ua kom ntev ib nrab -lub neej;
Lub hom phiaj kev xa khoom: Txuas daim siab- cov ligands tshwj xeeb (xws li sialic acid-depleted glycoprotein receptor ligands) rau saum npoo ntawm nanoparticles txhawm rau txhim kho cov tshuaj sib xyaw hauv daim siab;
Tswj kev tso tawm: Teb cov nanocarriers (xws li pH-sensitive ones) tuaj yeem tso tshuaj ntawm cov qog los yog qhov chaw mob, txo cov kab mob.
Kev tshawb fawb nce qib:
Liposome xa tshuab tau siv rau cov tshuaj peptide xws li insulin, tab sis kev thauj khoom ntawm Survodutide yuav tsum tau hais txog;
Polymer nanoparticles (xws li PLGA) tuaj yeem ua tiav kev tso tawm los ntawm kev tswj tus nqi degradation, tab sis kev sib cuam tshuam ntawm cov cab kuj thiab cov tshuaj yuav tsum tau ua kom zoo dua.
Microfluidic technology- pab xa khoom
Cov txheej txheem txheej txheem: Microfluidic chips tuaj yeem tswj tau qhov sib xyaw, emulsification thiab kho cov txheej txheem ntawm cov tshuaj daws teeb meem, thiab npaj monodisperse microspheres lossis microcapsules.
Muaj peev xwm siv tau:
Particle loj homogenization: Tsis txhob tso tawm tus cwj pwm tsis sib xws los ntawm qhov dav particle loj faib ntawm microspheres npaj los ntawm cov txheej txheem ib txwm muaj;
High-kev tshuaj ntsuam xyuas: ceev nrooj optimize cov formulation tsis (xws li polymer concentration, txaus tus nqi piv), accelerating txoj kev loj hlob;
Integrated ntau lawm: Muab 3D luam ntawv thev naus laus zis kom ua tiav kev npaj ntau npaum li cas.
Kev tshawb fawb nce qib:
Microfluidic thev naus laus zis tau siv los npaj PLGA microspheres encapsulating GLP-1 analogues, ua tiav kev tso tawm tas li rau ob peb lub lis piam mus rau ntau lub hlis;
Lub microfluidic formulation ntawm Survodutide yuav tsum tau kuaj xyuas rau nws cov kev tiv thaiv ntawm peptide conformation.
Physical and Chemical Delivery Systems
Kev siv lub hauv paus ntsiab lus: Siv lub cev txhais tau tias xws li ultrasound, laser, thiab hluav taws xob teb los txhawb cov tshuaj transdermal los yog mucosal absorption, los yog tso tshuaj los ntawm kub / pH teb mechanisms.
Muaj peev xwm siv tau:
Tsis yog -kev xa tawm: Cov tshuaj tiv thaiv kab mob los yog kev nqus pa tuaj yeem txhim kho kev ua raws li tus neeg mob, tshwj xeeb tshaj yog rau cov neeg mob rog;
Hauv cheeb tsam siab: Rau MASH, cov tshuaj tuaj yeem xa mus rau daim siab cov ntaub so ntswg los ntawm ultrasound-targeted microbubble disruption (UTMD) technology;
Kev tso tawm ntse: Kub-sensitive hydrogels tuaj yeem o thiab tso tshuaj ntawm lub cev kub, txo qhov zaus ntawm kev tswj hwm.
Kev tshawb fawb nce qib:
Transdermal tus me nyuam yuav tsum tau daws qhov teeb meem ntawm qhov hnyav molecular thiab muaj zog hydrophilicity ntawm Survodutide, uas ua rau muaj teeb meem ntawm transdermal barrier;
UTMD thev naus laus zis tau ua tiav hauv cov qauv tsiaj me rau lub siab- phiaj xwm xa cov tshuaj insulin-zoo li kev loj hlob zoo (IGF-1).
Cytokine los yog kev loj hlob zoo sib txuas ua ke
Cov ntsiab lus tseem ceeb: Txuas Survodutide nrog cytokines (xws li FGF21) lossis cov khoom siv tshuaj tiv thaiv kab mob kom ua tiav cov ntaub so ntswg- tshwj xeeb xa khoom los ntawm lawv lub hom phiaj cov khoom.
Muaj peev xwm siv tau:
Synergistic effect: FGF21 tuaj yeem txhim kho daim siab steatosis, thiab nws cov kev sib xyaw ua ke nrog Survodutide tuaj yeem txhim kho cov nyhuv kho ntawm MASH;
Targeting: Antibody -conjugated drug (ADC) thev naus laus zis tuaj yeem txheeb xyuas cov kab mob siab lossis cov kab mob siab hepatic stellate.
Kev tshawb fawb nce qib:
Cov kev tshawb fawb thaum ntxov yuav tsum tau txheeb xyuas qhov ruaj khov ntawm kev sib txuas thiab kev tuav pov hwm ntawm ob lub hom phiaj ua haujlwm.
Preclinical thiab soj ntsuam kev tshawb fawb nce qib
Pharmacokinetic optimization
Kev hloov kho acylation ntawmSurvodutide txhaj tshuajtau ntev ntev li ib nrab-lub neej, tab sis cov nanocarriers lossis microsphere npaj yuav txo tau qhov kev hloov pauv ntawm cov tshuaj ntshav ntau ntxiv thiab txo cov kev mob plab hnyuv (xws li xeev siab, ntuav).
Targeted xa ntawv pov thawj
Hauv MASH qauv, cov nanocarriers lossis UTMD thev naus laus zis yuav tsum tau txheeb xyuas qhov kev txhim kho ntawm daim siab rog cov ntsiab lus thiab fibrosis los ntawm tsis yog -invasive biomarkers (xws li MRI-PDFF, ELF qhab nia).
Txhim kho kev ua raws li tus neeg mob
Txoj kev loj hlob ntawm transdermal thaj ua rau thaj los yog inhalation npaj yuav tsum sib npaug ntawm cov tshuaj tso tawm tus nqi nrog daim tawv nqaij / mucosal irritation.
Kev pom yav tom ntej
Lub tshuab xa tawm tshiab ntawm Survodutide yuav tsum tsom mus rau "precision, ntev -ntev, thiab kev nyab xeeb":
Lub hom phiaj luv luv -lub sij hawm: Txhim kho qhov ruaj khov ntawm cov txheej txheem txhaj tshuaj subcutaneous uas twb muaj lawm thiab txo qhov kev siv tshuaj ntau zaus;
Nruab nrab- lub hom phiaj lub sij hawm: Tsim lub siab- tsom rau nanocarriers lossis microsphere formulations los txhim kho cov nyhuv kho ntawm MASH;
Lub hom phiaj ntev -Lub hom phiaj: Tshawb nrhiav tsis yog- cov tshuab xa tawm (xws li hloov pauv thiab nqus tau pa) kom hloov pauv hom kev kho mob rau cov rog rog thiab cov kab mob metabolic.
Cov pa roj -dej interface ua raws li cov degrader rau cov tshuaj peptide.
Lub Degradation Mechanism ntawm Peptide Tshuaj ntawm Huab Cua -Dej Interface
Huab cua-dej interface (Air-Water Interface, AWI) yog ib qho tseem ceeb microenvironment rau kev sib cuam tshuam ntawm cov roj ntsha molecules. Nws cov khoom tshwj xeeb ntawm lub cev thiab tshuaj lom neeg ua rau muaj teeb meem loj rau kev ruaj ntseg ntawm cov tshuaj peptide (xws li Survodutide):
Hydrophobic kev sib cuam tshuam thiab kev hloov pauv
Ntawm cov pa roj-dej interface, dej molecules tsim ib qho kev txiav txim, uas ua rau muaj kev txhim kho hydrophobicity hauv cheeb tsam interface. Cov tshuaj Peptide (tshwj xeeb tshaj yog cov kab ke uas tsis muaj -polar amino acid residues) tau yooj yim adsorbed ntawm lub interface, thiab lawv cov hydrophobic sab chains cuam tshuam nrog lub interface, yuam cov peptide saw kom undergo conformational rearrangement. Piv txwv li, thaum tus qauv peptide LK raug ntxias kom nthuav tawm los ntawm urea ntawm cov pa roj - dej interface, - cov qauv ntawv tau ruaj khov, tab sis tag nrho cov kev sib haum xeeb tsis zoo, ua rau poob ntawm cov khoom siv roj ntsha.
Mechanical stress and fracture risk
Qhov nro ntawm qhov sib txuas (kwv yees li 72 mN / m) siv lub zog tensile ntawm peptide saw, uas tuaj yeem ua rau cov neeg kho tshuab puas. Rau ntev - saw peptides (xws li 35-amino acid sequence ntawm Survodutide), kev sib txuas adsorption tuaj yeem ua rau muaj kev pheej hmoo ntawm peptide saw tawg, tshwj xeeb tshaj yog nyob rau ntawm qhov chaw hloov kho acylated (xws li -Glu-diacid18 sab saw), ntxiv rau kev ruaj ntseg ntawm cov tshuaj.
Oxidation thiab tshuaj degradation
Ntawm cov pa roj -dej interface, qhov concentration ntawm oxygen molecules yog siab, thiab lub interface hluav taws xob teb (mus txog 10⁸ V / m) yuav ua rau kom cov dawb radicals, ua rau peptide saw oxidation thiab degradation. Piv txwv li, hydroxyl radical (·OH) tuaj yeem tawm tsam peptide daim ntawv cog lus lossis cov pab pawg sab nrauv, ua rau tawg lossis hloov kho, thiab txo cov tshuaj ua haujlwm.
Cov yam ntxwv ntawm molecular thiab kev sib cuam tshuam ntawm Survodutide
Survodutide txhaj tshuajyog ib qho acylated peptide dual- lub hom phiaj agonist, thiab nws cov qauv molecular cov yam ntxwv ua rau nws rhiab heev rau kev puas tsuaj ntawm cov pa roj- dej interface:
Qhov tsis zoo ntawm kev hloov kho acylated
Lub C-terminal ntawm Survodutide yog acylated los ntawm -Glu-diacid18 sab saw kom txuas nws ib nrab- lub neej. Txawm li cas los xij, qhov ntev - saw alkyl qauv ntawm pawg acyl tuaj yeem txhim kho nws txoj kev nyiam adsorption ntawm cov pa roj- dej interface, ua rau muaj kev pheej hmoo ntawm kev hloov pauv. Tsis tas li ntawd, cov acyl bonds (xws li ester bonds los yog amide bonds) yog feem ntau tawg nyob rau hauv lub interface oxidation ib puag ncig, ua rau cov tshuaj inactivation.
Amino acid muaj pes tsawg leeg thiab kev sib cuam tshuam
Qhov sib lawv liag ntawm Survodutide muaj ntau yam hydrophobic amino acids (xws li Leu, Phe, Trp), thiab lawv cov chains sab yog nquag khi rau thaj tsam hydrophobic ntawm cov pa roj - dej interface, ua rau muaj kev tsis sib haum xeeb. Nyob rau tib lub sijhawm, hydrogen bond network ntawm qhov sib cuam tshuam tuaj yeem cuam tshuam nrog kev tsim cov hydrogen bonds hauv cov saw peptide, ntxiv cuam tshuam nws cov qauv theem nrab (xws li -helix lossis - ntawv).
Qhov yuav tsum tau muaj kev ruaj ntseg ntawm dual - lub hom phiaj mechanism
Survodutide yuav tsum tau ua kom ib txhij qhib GLP-1 thiab GCGR receptors, thiab nws cov kev sib raug zoo (xws li qhov kev sib haum xeeb ntawm cov receptor khi hnab tshos) yuav tsum muaj kev ntseeg siab heev. Cov kev hloov pauv uas tshwm sim los ntawm cov roj-dej cuam tshuam tuaj yeem cuam tshuam nws txoj kev muaj peev xwm khi rau cov receptors thiab txo qhov ua tau zoo ntawm cov tshuaj.
Countermeasures: Los ntawm Molecular Design rau Formulation Optimization
Txhawm rau txo qhov kev puas tsuaj ntawm cov pa roj- dej interface ntawm Survodutide, kev ua kom zoo dua yuav tsum tau ua los ntawm ntau qhov ntev xws li kev tsim qauv molecular, txheej txheem tsim, thiab kev tswj hwm txoj kev:
Molecular Design: Txhim kho Interface Stability
Qhia Ring Structures: Los ntawm lub nplhaib- tsim cov kev hloov kho (xws li kev tsim cov nyiaj disulfide los yog sab- chain cyclization), txoj kev ywj pheej conformational ntawm cov saw peptide raug txwv, txo qhov kev pheej hmoo ntawm denaturation induced los ntawm kev sib cuam tshuam adsorption.
Optimizing Hydrophobic/Polar Balance: Kho cov amino acid muaj pes tsawg leeg, txo qhov kev faib ua feem ntawm hydrophobic residues, los yog qhia txog kev hloov kho hydrophilic (xws li polyethylene glycolization), kom txo tau qhov nyiam ntawm kev sib cuam tshuam adsorption.
Strengthening Acylation Bond Stability: Siv cov kev sib txuas ruaj khov acylation ntau dua (xws li thioester bonds lossis carbon-carbon bonds), los yog qhia cov pab pawg antioxidant (xws li vitamin E derivatives), los tiv thaiv acylated sab chains los ntawm oxidative degradation.
Txheej txheem txheej txheem: Tiv thaiv Peptide Conformation
Ntxiv Surfactants: Ntxiv cov uas tsis yog- ionic surfactants (xws li polysorbate 80) rau cov qauv, los ntawm kev sib tw adsorption, tuav cov roj- dej interface thiab txo qhov kev sib cuag ncaj qha ntawm Survodutide nrog lub interface.
Optimizing Freeze-Drying Protectants: Siv khov-cov tshuaj tiv thaiv kom qhuav xws li sucrose thiab mannitol, tswj kev sib haum xeeb ntawm cov saw peptide thaum ziab thiab tiv thaiv kev sib tshuam -induced aggregation or degradation.
Nanocarrier Encapsulation: Siv liposomes los yog polymer nanoparticles los encapsulate Survodutide, ua ib lub cev barrier rau cais cov pa roj - dej interface thiab ua tiav kev tso tawm.
Txoj kev tswj hwm: Txo qhov cuam tshuam cuam tshuam
Tsim ntawm Pre-Syringes puv: Siv cov roj inert (xws li nitrogen) los sau lub taub hau ntawm cov koob txhaj tshuaj kom txo tau qhov chaw sib cuag ntawm cov tshuaj tov thiab cua, txo qhov kev pheej hmoo ntawm kev cuam tshuam -induced degradation.
Fast Injection Technology: Optimizing txhaj ceev kom luv lub sij hawm nyob ntawm cov tshuaj nyob rau hauv lub koob los yog syringe, txo qhov raug cov pa roj - dej interface.
Cim npe nrov: survodutide txhaj tshuaj, lwm tus neeg, manufacturers, hoobkas, lag luam wholesale, yuav, nqe, tej, kev muag khoom